Evaluation of Physician Knowledge of Safety and Safe Use Information for Intravitreal Aflibercept Injection in Europe: A Second Survey of Physicians Following Dissemination of Updated Risk-Minimization Materials-Reference-Cited by-同舟云学术

Evaluation of Physician Knowledge of Safety and Safe Use Information for Intravitreal Aflibercept Injection in Europe: A Second Survey of Physicians Following Dissemination of Updated Risk-Minimization Materials

Published:2023-12-05 Issue:1 Volume:38 Page:63-73
ISSN:1178-2595
Container-title:Pharmaceutical Medicine
language:en
Short-container-title:Pharm Med

Author:

Zografos Laurie J.,Andrews Elizabeth,Wolin Dan L.,Calingaert Brian,Davenport Eric K.,Michel Alexander,Latocha Margarete,Schmidt-Ott Ursula Maria,Lovic Nejra,Brunck Lynne R.,Johnson Kristian T.,Suzart-Woischnik Kiliana

Funder

Bayer AG

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40290-023-00506-7.pdf

Reference19 articles.

1. Eylea summary of product characteristics. European Medicines Agency. 2023. https://www.ema.europa.eu/en/documents/product-information/eylea-epar-product-information_en.pdf. Accessed 31 May 2023.

2. Csaky K, Do DV. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol. 2009;148(5):647–56. https://doi.org/10.1016/j.ajo.2009.06.014.

3. Jeganathan VS, Verma N. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration. Curr Opin Ophthalmol. 2009;20(3):223–5. https://doi.org/10.1097/ICU.0b013e328329b656.

4. European Medicines Agency. Assessment report: Eylea (aflibercept). European Medicines Agency; 2013.

5. Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport EK, Hollis KA, et al. Physician and patient knowledge of safety and safe use information for aflibercept in Europe: evaluation of risk-minimization measures. Pharmaceut Med. 2019;33(3):219–33. https://doi.org/10.1007/s40290-019-00279-y.